Integral Diagnostics Limited

ASX:IDX Stock Report

Market Cap: AU$701.7m

Integral Diagnostics Future Growth

Future criteria checks 4/6

Integral Diagnostics is forecast to grow earnings and revenue by 54.1% and 15.4% per annum respectively. EPS is expected to grow by 59.9% per annum. Return on equity is forecast to be 14% in 3 years.

Key information

54.1%

Earnings growth rate

59.9%

EPS growth rate

Healthcare earnings growth24.1%
Revenue growth rate15.4%
Future return on equity14.0%
Analyst coverage

Good

Last updated20 Dec 2024

Recent future growth updates

Recent updates

Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Feb 21
Some Investors May Be Worried About Integral Diagnostics' (ASX:IDX) Returns On Capital

Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Nov 22
Shareholders Will Probably Hold Off On Increasing Integral Diagnostics Limited's (ASX:IDX) CEO Compensation For The Time Being

Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

Feb 20
Integral Diagnostics' (ASX:IDX) Shareholders Will Receive A Smaller Dividend Than Last Year

These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Dec 14
These 4 Measures Indicate That Integral Diagnostics (ASX:IDX) Is Using Debt Extensively

Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

May 26
Should You Think About Buying Integral Diagnostics Limited (ASX:IDX) Now?

Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Feb 28
Integral Diagnostics (ASX:IDX) Is Paying Out Less In Dividends Than Last Year

Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Feb 25
Integral Diagnostics Limited (ASX:IDX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Oct 29
Shareholders Would Not Be Objecting To Integral Diagnostics Limited's (ASX:IDX) CEO Compensation And Here's Why

Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

Sep 13
Does Integral Diagnostics (ASX:IDX) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Jun 04
An Intrinsic Calculation For Integral Diagnostics Limited (ASX:IDX) Suggests It's 22% Undervalued

Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

May 14
Should You Be Adding Integral Diagnostics (ASX:IDX) To Your Watchlist Today?

Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

May 03
Is Integral Diagnostics Limited (ASX:IDX) A Smart Choice For Dividend Investors?

We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Apr 16
We Think Integral Diagnostics (ASX:IDX) Can Stay On Top Of Its Debt

Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Mar 27
Is It Too Late To Consider Buying Integral Diagnostics Limited (ASX:IDX)?

Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

Mar 17
Is Integral Diagnostics Limited's (ASX:IDX) Stock's Recent Performance A Reflection Of Its Financial Health?

The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About

Mar 07
The Trends At Integral Diagnostics (ASX:IDX) That You Should Know About

Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend

Feb 25
Here's What We Like About Integral Diagnostics' (ASX:IDX) Upcoming Dividend

Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?

Feb 23
Is Integral Diagnostics Limited (ASX:IDX) Popular Amongst Institutions?

Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?

Feb 13
Have Insiders Been Selling Integral Diagnostics Limited (ASX:IDX) Shares?

Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price

Feb 03
Integral Diagnostics Limited's (ASX:IDX) Intrinsic Value Is Potentially 46% Above Its Share Price

Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)

Jan 24
Here's What We Learned About The CEO Pay At Integral Diagnostics Limited (ASX:IDX)

Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?

Jan 14
Should You Use Integral Diagnostics's (ASX:IDX) Statutory Earnings To Analyse It?

Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return

Jan 05
Shareholders Of Integral Diagnostics (ASX:IDX) Must Be Happy With Their 201% Total Return

Is Integral Diagnostics (ASX:IDX) A Risky Investment?

Dec 26
Is Integral Diagnostics (ASX:IDX) A Risky Investment?

At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?

Dec 17
At AU$4.30, Is It Time To Put Integral Diagnostics Limited (ASX:IDX) On Your Watch List?

What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend

Dec 08
What To Know Before Buying Integral Diagnostics Limited (ASX:IDX) For Its Dividend

Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture

Nov 29
Returns On Capital At Integral Diagnostics (ASX:IDX) Paint An Interesting Picture

Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?

Nov 19
Is Integral Diagnostics Limited's (ASX:IDX) Shareholder Ownership Skewed Towards Insiders?

Earnings and Revenue Growth Forecasts

ASX:IDX - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2027857676614410
6/30/2026806546012912
6/30/202563228398011
6/30/2024470-614266N/A
3/31/2024463-592962N/A
12/31/2023456-582062N/A
9/30/2023449-162467N/A
6/30/2023441252367N/A
3/31/2023418232056N/A
12/31/2022395211745N/A
9/30/2022378181341N/A
6/30/202236115937N/A
3/31/2022361181441N/A
12/31/2021360221844N/A
9/30/2021356263457N/A
6/30/2021351314970N/A
3/31/2021333325473N/A
12/31/2020315325976N/A
9/30/2020295284465N/A
6/30/2020276232854N/A
3/31/2020263221947N/A
12/31/201925021939N/A
9/30/2019241211237N/A
6/30/2019232211534N/A
3/31/2019222191430N/A
12/31/2018211171326N/A
9/30/2018200161426N/A
6/30/2018189151527N/A
3/31/201818715N/A27N/A
12/31/201718515N/A27N/A
9/30/201718215N/A25N/A
6/30/201718015N/A23N/A
3/31/201717716N/A26N/A
12/31/201617516N/A30N/A
9/30/201617114N/A27N/A
6/30/201616811N/A24N/A
3/31/201616511N/A22N/A
12/31/201516211N/A20N/A
9/30/20151578N/A18N/A
6/30/20151515N/A17N/A
6/30/201443N/A4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: IDX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: IDX is expected to become profitable in the next 3 years.

Revenue vs Market: IDX's revenue (15.4% per year) is forecast to grow faster than the Australian market (5.8% per year).

High Growth Revenue: IDX's revenue (15.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IDX's Return on Equity is forecast to be low in 3 years time (14%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Integral Diagnostics Limited is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
Thomas YeoBarrenjoey Markets Pty Limited
Saul HadassinBarrenjoey Markets Pty Limited